Table 1.
Characteristics of the Study Population
| Study population (n = 228) | |
|---|---|
| Male, % (n) | 57.9 (132) |
| Age (year), median (IQR) | 10.7 (8.4–12.9) |
| Duration of follow up (year), median (IQR) | 2.4 (1.1–4.9) |
| Tobacco exposure, % (n) | 57.9 (132) |
| Aeroallergen sensitization | 48.2 (110) |
| Asthma therapy, % (n) | |
| Only as needed SABA | 25.0 (57) |
| ICS use | 68.4 (156) |
| ICS monotherapy | 52.2 (119) |
| LTRA monotherapy | 6.6 (15) |
| ICS+LTRA | 8.3 (19) |
| ICS+LABA | 7.5 (17) |
| ICS+LABA+LTRA | 0.4 (1) |
| Asthma severity, % (n) | |
| Intermittent | 25.9 (59) |
| Mild persistent | 51.3 (117) |
| Moderate persistent | 15.4 (35) |
| Severe persistent | 7.5 (17) |
| Allergic rhinitis, % (n) | 41.9 (95) |
| FeNO (ppb) | 19 (15–27) |
| PACT | 22 (18–25) |
| ACT | 22 (18–24) |
| PAQLQ, median (IQR) | 6.0 (4.9–6.6) |
| Symptoms | 5.2 (4.2–6.4) |
| Emotional functions | 6.0 (5.1–6.6) |
| Activity limitation | 6.2 (5.2–6.9) |
| Spirometry, median (IQR) | |
| FEV1 (% predicted) | 93 (87–103) |
| FEV1/FVC (ratio) | 98 (93–105) |
| FEF25–75 (% predicted) | 90 (79–112) |
ACT/PACT, asthma control test/pediatric asthma control test; FEF25–75, forced expiratory flow at 25% to 75% of forced vital capacity; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FEV1/FVC, the ratio of “forced expiratory volume in 1 s” to “forced vital capacity”; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting beta-2 agonist; LTRA, leukotriene receptor antagonist; PAQLQ, Pediatric Asthma Quality of Life Questionnaire; SABA, short acting beta-2 agonist.